Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP5K1C | O60331 | 17/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | PIP5K1B | O14986 | 3/20 | 0.49 |
| ▸ | PIP5K1A | Q99755 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.49 |
| ▸ | PI4KA | P42356 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10242753 | 0.88 | CDK9 (0.51) | PIP5K1CPIK3CACDK9 | |
| SCHEMBL1461986 | 0.88 | IRAK4 (0.49) | PIP5K1CPIK3CAMAPK8MAPK10MAPK14 | |
| SCHEMBL10241819 | 0.85 | PIP5K1C (0.54) | PIP5K1CPIK3CAMAPK8MAPK10MAPK14 | |
| SCHEMBL10285782 | 0.84 | DYRK1A (0.46) | MAPK8MAPK10MAPK14CDK9 | |
| SCHEMBL10243992 | 0.83 | PIP5K1C (0.53) | PIP5K1CPIK3CAMAPK8MAPK10MAPK14 | |
| SCHEMBL10242086 | 0.78 | PIP5K1C (0.48) | PIP5K1CPIK3CAMAPK8MAPK10MAPK14 | |
| SCHEMBL10244215 | 0.78 | PIP5K1C (0.48) | PIP5K1CPIK3CAMAPK8MAPK10MAPK14 | |
| SCHEMBL1949675 | 0.77 | CCNT1 (0.60) | CDK9 | |
| SCHEMBL10241728 | 0.75 | CDK9 (0.61) | CDK9 | |
| SCHEMBL10242935 | 0.75 | CDK9 (0.61) | CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | PIP5K1C 476/4885PIK3CA 218/4885MAPK8 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.